 |
| AbbVie CEO Richard Gonzalez |
Now that AbbVie ($ABBV) has hammered out its $55 billion takeover deal for Shire ($SHPG), analysts are looking for the next big biopharma tax inversion deal. And UBS analyst Guillaume van Renterghem tells Bloomberg that Switzerland's Actelion ($ATLN)--a longtime favorite among takeover targets--is a good possibility as the industry consolidates into low-tax domiciles. The news service also raised the prospect of a takeover of the generic drug company Perrigo. But bigger than both would be AbbVie itself, which could emerge as a megamerger target once it completes its Shire buyout and moves its tax residency. Story